Clinical Advances in Diabetes Management with GLP-1 Agonists

Worldwide prevalence rates for type 2 diabetes mellitus (T2DM) vary considerably. The prevalence of T2DM in Europe is expected to increase 20% within the next 20 years. Effective management of diabetes is a dynamic and individualized process, requiring an appropriate treatment regimen and long-term monitoring. New classes of antihyperglycemic agents are being developed which may help further individualize care with the goal of achieving glycemic control in T2DM.

Looking Beyond the Surface of Better Glucose Control With GLP-1 Agonists
Join Drs Leahy, Rea, Leiter, and Pieber for a discussion on the benefits of incorporating glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus.
September 21, 2015
Tailored Therapy for the Complex Diabetes Patient in Primary Care
Join Dr Jendle as he discusses challenges in the management of glycemic control in patients with type 2 diabetes.
March 24, 2015
What Do Primary Care Physicians Need to Know About the Safe and Effective Use of GLP-1 RAs?
Join Drs Gallwitz, Martinez, and Pratley as they review clinical and practical issues related to GLP-1 RA use in primary care.
November 26, 2014
Progressive T2DM Management Beyond Glycemia -- Where Do GLP-1 RAs Fit Into the Treatment Algorithm?
Join Drs Nauck, Vilsbøll, and Jendle as they discuss the clinical profiles of GLP-1 RAs and their role in the treatment of T2DM.
November 6, 2014
GLP-1 Receptor Agonists: A Cornerstone of Modern Diabetes Management
Join Drs Vilsboll, Jendle, Zinman, Charbonnel, and Nauck as they review the role of GLP-1 RAs in the management of T2DM.
August 22, 2014
Initiating Diabetes Therapy With GLP-1 Receptor Agonists in Primary Care
Work through these 2 cases and receive feedback on the consequences that your management choices have on your patients with T2DM.
May 30, 2014
GLP-1 Receptor Agonists: Targeting Comprehensive Vascular Risk Control In Type 2 Diabetes Management
Join Dr Meier to review the importance of CV risk reduction in T2DM patients and the role of GLP-1 RAs in a comprehensive treatment plan.
April 30, 2014

France

Germany

Portugal

Spain

Steering Committee Chair

Tina Vilsbøll, MD, DMSc
Head of Diabetes Research
Gentofte Hospital
University of Copenhagen
Copenhagen, Denmark

Steering Committee Members

Michael A. Nauck, MD, PhD
Professor of Internal Medicine; Head, Specialist Centre for Diabetes and Metabolic Diseases, Diabetes Centre, Bad Lauterberg, Germany
Johan Jendle, MD, PhD
Associate Professor, Endocrine and Diabetes Center, Karlstad Hospital, Sweden
Eduard Montanya, MD, PhD
Professor, Department of Clinical Sciences, University of Barcelona; Chief, Department of Diabetes, Bellvitge University Hospital, Barcelona, Spain

Jack Leahy, MD
Professor of Medicine; Chief of Endocrinology, Diabetes, and Metabolism Unit, University of Vermont College of Medicine, Burlington, Vermont, USA

John Petrie, MD, PhD
Professor of Diabetic Medicine, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK

Sebastiano Filetti, MD
Department of Clinical Sciences, University of Rome "La Sapienza", Rome, Italy

Disclaimer: This Clinical Advances is intended for an audience of healthcare professionals located outside the United States.

Supported by an independent educational grant from
Novo Nordisk Global

Downloadable Slide Kit

Clinical Advances in Diabetes Management with GLP-1 Agonists
A peer-reviewed slide kit addressing the importance of appropriate glycemic control in people with T2DM and the role of GLP-1 receptor agonists in hyperglycemia management.

Clinical Articles

Steering Committee

Tina Vilsbøll, MD, DMSc

Tina Vilsbøll, MD, DMSc, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Eli Lilly and Company; Merck Sharp & Dohme Corp.; Novo Nordisk
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Merck Sharp & Dohme Corp.; Novo Nordisk
Received grants for clinical research from: Merck Sharp & Dohme Corp.; Novo Nordisk

Sebastiano Filetti, MD

Sebastiano Filetti, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Novo Nordisk
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corporation; Novo Nordisk
Received grants for clinical research from: Eli Lilly and Company

Johan H. Jendle, MD, PhD

Johan H. Jendle, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Medtronic, Inc.; Novo Nordisk; Pfizer Inc.
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Merck Sharp & Dohme Corp.; Novo Nordisk; Pfizer Inc.

Jack L. Leahy, MD,

Jack L. Leahy, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Janssen Global Services LLC; Merck & Co., Inc.; Novo Nordisk; sanofi-aventis; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: sanofi-aventis
Received grants for clinical research from: Takeda Pharmaceuticals North America, Inc.

Eduard Montanya, MD, PhD

Eduard Montanya, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Intarcia Therapeutics, Inc.; Novo Nordisk
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck Sharp & Dohme Corp.; Novo Nordisk
Spouse owns stock, stock options, or bonds from: Almirall Prodesfarma, S.A.

Michael A. Nauck, MD, PhD

Michael A. Nauck, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amylin Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Berlin-Chemie AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Diartis Pharmaceuticals; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; GlaxoSmithKline; Intarcia Therapeutics, Inc.; MannKind Corporation; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; sanofi-aventis; Takeda Pharmaceuticals North America, Inc.; Versartis, Inc.; Wyeth Pharmaceuticals Inc.
Served as a speaker or a member of a speakers bureau for: Amylin Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Berlin-Chemie AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Diartis Pharmaceuticals; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; GlaxoSmithKline; Intarcia Therapeutics, Inc.; MannKind Corporation; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; sanofi-aventis; Takeda Pharmaceuticals North America, Inc.; Versartis, Inc.; Wyeth Pharmaceuticals Inc.
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Berlin-Chemie AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; GlaxoSmithKline; Merck Sharp & Dohme Corp.; MetaCure Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Roche; Tolerx, Inc.

John R. Petrie, MD, PhDL

John R. Petrie, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Novo Nordisk; Roche; sanofi-aventis; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: GlaxoSmithKline; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: JDRF; Merck Serono
Has a research agreement with: Itamar Medical

	With pending approval of multiple once-weekly GLP-1 RAs for T2DM, in which patients do you believe they will be primarily used?
		In patients already on insulin
		In patients who are at high risk for hypoglycemia
		In patients with moderate renal impairment
		In patients already on a GLP-1 RA
		In patients who do not reach their HbA1c goal on oral therapy